Core Scientific reported massive deterioration in profitability with operating losses expanding over 1,000% while burning through 63% of its cash despite massive capital expansion.
The company is experiencing severe financial distress with operating income declining from -$19M to -$246M while simultaneously spending $729M in capex (up 668%). The disclosure of material weaknesses in internal controls combined with heavy dependence on a single customer creates significant execution and concentration risks for investors.
Core Scientific's financials show a company in aggressive expansion mode but with deteriorating fundamentals - gross profit collapsed 69% to $38M while operating losses exploded over 1,000% to -$246M. Despite burning through $628M in cash (ending at $311M), the company dramatically increased capex to $729M and grew total assets 47% to $2.3B, suggesting major infrastructure investments that have not yet generated returns. The combination of massive cash burn, expanding losses, and quintupling current liabilities to $781M signals potential liquidity stress despite strong operating cash flow of $278M.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Capital expenditure jumped 667.7% — major investment cycle underway; assess returns on deployment.
Operating cash flow surged 548.7% — exceptional cash generation, highest quality earnings signal.
Current liabilities surged 480.7% — significant near-term obligations; verify ability to meet short-term debt.
Net income grew 78.1% — bottom-line growth signals improving overall business health.
Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.
R&D investment increased 64.7% — signals commitment to future product development, though near-term margin impact.
Cash declined 62.8% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Asset base grew 46.8% — expansion through organic growth, acquisitions, or capital deployment.
SG&A up 40% — significant increase in sales or administrative costs, monitor impact on operating leverage.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →